← Product Code [IYO](/submissions/RA/subpart-b%E2%80%94diagnostic-devices/IYO) · K042540
# PHILIPS IU22 ULTRASOUND SYSTEM (K042540)
_Philips Ultrasound, Inc. · IYO · Oct 4, 2004 · Radiology · SESE_
**Canonical URL:** https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/IYO/K042540
## Device Facts
- **Applicant:** Philips Ultrasound, Inc.
- **Product Code:** [IYO](/submissions/RA/subpart-b%E2%80%94diagnostic-devices/IYO.md)
- **Decision Date:** Oct 4, 2004
- **Decision:** SESE
- **Submission Type:** Traditional
- **Regulation:** 21 CFR 892.1560
- **Device Class:** Class 2
- **Review Panel:** Radiology
- **Attributes:** Pediatric, 3rd-Party Reviewed
## Indications for Use
The iU22 system and transducers are intended for diagnostic ultrasound imaging and fluid flow analysis of the human body.
## Device Story
The iU22 is a diagnostic ultrasound system using piezoelectric transducer arrays to convert electronic voltage pulses into ultrasonic pressure waves. The system processes echoes and Doppler shift frequencies from body tissues and blood flow to generate real-time images and flow measurements. It supports B-mode, M-mode, Pulsed Wave Doppler (PWD), Continuous Wave Doppler (CWD), and Color Doppler (including Amplitude Doppler). Advanced features include SonoCT (spatial compounding), XRES (speckle reduction), harmonic imaging, contrast imaging, 3D imaging, and Extended Field of View (EFOV). Operated by clinicians in clinical settings, the system provides anatomical measurements and analysis packages to assist in diagnosis. Output is displayed on the system monitor for physician interpretation to guide clinical decision-making, such as biopsy guidance or monitoring of fetal development and cardiac function.
## Clinical Evidence
Bench testing only. The device was evaluated for safety and effectiveness through comparison of technological characteristics, acoustic output measurements, and adherence to electrical/physical safety standards. No clinical study data was required or provided for this 510(k) clearance.
## Technological Characteristics
Diagnostic ultrasound system utilizing piezoelectric transducer arrays. Modes: B, M, PWD, CWD, Color/Amplitude Doppler. Features: SonoCT, XRES, harmonic imaging, contrast imaging, 3D imaging, EFOV. Connectivity: Standard ultrasound system architecture. Safety: Acoustic output levels comply with FDA limits; materials evaluated for biocompatibility; electrical/physical safety per applicable standards.
## Regulatory Identification
An ultrasonic pulsed echo imaging system is a device intended to project a pulsed sound beam into body tissue to determine the depth or location of the tissue interfaces and to measure the duration of an acoustic pulse from the transmitter to the tissue interface and back to the receiver. This generic type of device may include signal analysis and display equipment, patient and equipment supports, component parts, and accessories.
## Special Controls
*Classification.* Class II (special controls). A biopsy needle guide kit intended for use with an ultrasonic pulsed echo imaging system only is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 892.9.
## Predicate Devices
- QLAB ([K040227](/device/K040227.md))
- LV Analysis ([K022824](/device/K022824.md))
- M2424 ([K022303](/device/K022303.md))
## Submission Summary (Full Text)
> This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com.
>
> Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/).
{0}------------------------------------------------
K04254D
OC7 4 - 2004
# 510(k) Summary of Safety and Effectiveness
This summary of safety and effectiveness information is submitted in accordance with 21CFR §807.92.
## 1) Submitter's name, address, telephone number, contact person
Philips Ultrasound 22100 Bothell Everett Highway Telephone: (425) 487-7312 Facsimile: (425) 487-8666 E-mail: Lynn.harmer@philips.com
Contact Person: Lynn Harmer
Date prepared: 21 July 2004
## 2) Name of the device, including the trade or proprietary name if applicable, the common or usual name, and the classification name, if known:
| Common/Usual Name: | Diagnostic ultrasound system with accessories |
|--------------------|-----------------------------------------------|
| Proprietary Name: | iU22 ultrasound system |
| Classification Name | 21 CFR Section | Product Code |
|------------------------------------------|----------------|--------------|
| Ultrasonic Pulsed Doppler Imaging System | 892.1550 | 90-IYN |
| Ultrasonic Pulsed Echo Imaging System | 892.1560 | 90-IYO |
| Diagnostic Ultrasonic Transducer | 892.1570 | 90-ITX |
### 3) Substantially Equivalent Devices
Philips Ultrasound believes that the iU22 system and transducers are substantially equivalent to the following currently marketed devices:
QLAB (K040227;) LV Analysis (K022824;) and M2424 (K022303)
{1}------------------------------------------------
# 4) Device Description & Technical Comparison to Predicate Devices
The iU22 system and transducer(s) function in a manner identical to all diagnostic ultrasound systems and transducers. The system circuitry generates an electronic voltage pulse, which is transmitted to the transducer. In the transducer, a piezo electric array converts the electronic pulse into an ultrasonic pressure wave. When coupled to the body, the pressure wave transmits through body tissues. The Doppler functions of this system process the Doppler shift frequencies from the echoes of moving targets (such as blood), to detect and graphically display the Doppler shifts of these tissues as flow.
The iU22 system gives the operator the ability to measure anatomical structures, and offers analysis packages that provide information used by competent health care professionals to make a diagnosis.
## 5) Intended Use
The iU22 system and transducers are intended for diagnostic ultrasound imaging and fluid flow analysis of the human body.
## 6) Conclusion
The iU22 system and transducers are substantially equivalent in safety and effectiveness to the predicate systems and transducers listed in item 3 above.
- . The systems are intended for diagnostic ultrasound imaging and fluid flow analysis.
- The systems have the same gray-scale and Doppler capabilities. .
- The systems use essentially the same technologies for imaging, Doppler functions and . signal processing.
- . The systems have acoustic output levels below the applicable FDA limits.
- The systems are manufactured of materials with materials that have been evaluated . and found to be safe for its application.
- . The systems are designed and manufactured to applicable electrical and physical safety standards.
{2}------------------------------------------------
DEPARTMENT OF HEALTH & HUMAN SERVICES
Image /page/2/Picture/1 description: The image is a black and white logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The bird is facing towards the upper right. Encircling the bird is the text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" in a circular arrangement.
Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850
OCT 4 - 2004
Phillips Ultrasound, Inc. % Ms. Michelle S. Lee Underwriters Laboratories, Inc. 2600 NW Lake Road CAMAS WA 98607
Re: K042540
ﺎ ﺍﻟﻤﺴﺘﻘﻠﺔ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟﻤﺘﺤﺪﺓ ﺍﻟ
Trade Name: iU22 Diagnostic Ultrasound System Regulation Number: 21 CFR 892.1550 Regulation Name: Ultrasonic pulsed doppler imaging system Regulation Number: 21 CFR 892.1560 Regulation Name: Ultrasonic pulsed echo imaging system Regulation Number: 21 CFR 892.1570 Regulation Name: Diagnostic Ultrasonic transducer Regulatory Class: II Product Code: 90 IYN, IYO, and ITX Dated: September 17, 2004 Received: September 20, 2004
Dear Ms. Lee:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced w onate formed your booms been is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been May 20, 1910, and vith the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
This determination of substantial equivalence applies to the following transducers intended for use with the iU22 Diagnostic Ultrasound System, as described in your premarket notification:
#### Transducer Model Number
### X3-1 दर्श्-रि
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that
{3}------------------------------------------------
· Page 2 - Ms. Lee
FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
This determination of substantial equivalence is granted on the condition that prior to shipping the first device, you submit a postclearance special report. This report should contain complete information, including acoustic output measurements based on production line devices, requested in Appendix G, (enclosed) of the Center's September 30, 1997 "Information for Manufacturers Seeking Marketing Clearance of Diagnostic Ultrasound Systems and Transducers." If the special report is incomplete or contains unacceptable values (e.g., acoustic output greater than approved levels), then the 510(k) clearance may not apply to the production units which as a result may be considered adulterated or misbranded.
The special report should reference the manufacturer's 510(k) number. It should be clearly and prominently marked "ADD-TO-FILE" and should be submitted in duplicate to:
> Food and Drug Administration Center for Devices and Radiological Health Document Mail Center (HFZ-401) 9200 Corporate Boulevard Rockville, Maryland 20850
This letter will allow you to begin marketing your device as described in your premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus permits your device to proceed to market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801, please contact the Office of Compliance at (301) 594-4591. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or at (301) 443-6597 or at its Internet address "http://www.fda.gov/cdrh/dsmamain.html".
If you have any questions regarding the content of this letter, please contact Rodrigo C. Perez at (301) 594-1212.
Sincerely yours.
Daniela Logemann
Nancy C. Brogdon Director, Division of Reproductive, Abdominal and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure(s)
{4}------------------------------------------------
# DIAGNOSTIC ULTRASOUND INDICATIONS FOR USE STATEMENT
510(k) Number: System:
iU22 Ultrasound System
Intended Use:
1022 Untrasound imaging or fluid flow analysis of the human body as follows:
| Clinical Application | | Mode of Operation (*includes simultaneous B-mode) | | | | | | |
|---------------------------|-----------------------------------------------------------|---------------------------------------------------|------|------|------|--------------------|---------------------|------------------------------------|
| General
(Track I only) | Specific
(Tracks I & III) | B | M | PWD | CWD | Color
Doppler** | Combined
(Spec.) | Other
(Spec.) |
| Ophthalmic | Ophthalmic | P | P | P | P | P | Notes 1, 3 | Notes 5, 6, 8,10,12, 13 |
| | Fetal | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 7, 8, 10, 12, 13 |
| | Abdominal | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 7, 8, 10, 11, 12, 13 |
| | Intra-operative
(Abdominal, Cardiac*, Spine, Vascular) | P/N* | P/N* | P/N* | P/N* | P/N* | Notes 1, 3 | Notes 5, 6, 8,10,12, 13 |
| Fetal Imaging
& Other | Intra-operative (Neuro.) | P | P | P | P | P | Notes 1, 3 | Notes 3, 5, 6, 10, 12, 13 |
| | Laparoscopic | P | P | P | P | P | Notes 1, 3 | Notes 8, 10, 12, 13 |
| | Pediatric | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 8, 9, 10, 12, 13 |
| | Small Organ (breast, thyroid, testicle) | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 8, 10, 11, 12, 13 |
| | Neonatal Cephalic | P | P | P | P | P | Notes 1, 3 | Notes 5, 8, 10, 12, 13 |
| | Adult Cephalic | P | P | P | P | P | Notes 1, 3, 4 | Notes 10, 13 |
| | Trans-rectal | P | P | P | P | P | Notes 1, 3 | Notes 5,6,10,11,12, 13 |
| | Trans-vaginal | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 7,10, 11,12, 13 |
| | Trans-urethral | | | | | | | |
| | Trans-esoph. (non-Cardiac) | | | | | | | |
| | Musculo-skel. (Conventional) | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 8,10, 12,13 |
| | Musculo-skel. (Superficial) | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 8, 10, 12,13 |
| | Intra-luminal | | | | | | | |
| | Other: Urology | P | P | P | P | P | Notes 1, 3 | Notes 5, 10, 12 |
| Cardiac | Cardiac Adult | P | P | P | P | P | Notes 1,2,3,4 | Notes 10, 11, 12, 13 |
| | Cardiac Pediatric | P | P | P | P | P | Notes 1,2,3,4 | Notes 10, 11, 12, 13 |
| | Trans-esophageal (Cardiac) | P | P | P | P | P | Notes 1,2,3,4 | Note 10 |
| | Other (Fetal Echo) | P | P | P | P | P | Notes 1,2,3,4 | Notes 5,10, 12, 13 |
| Peripheral | Peripheral vessel | P | P | P | P | P | Notes 1, 2, 3 | Notes 2, 3, 5, 6, 7, 8, 10, 12, 13 |
| | Cerebral Vascular | P | P | P | P | P | Notes 1, 2, 3 | Notes 5, 6, 8, 10, 12, 13 |
N= new indication; P= previously cleared; E= added under Appendix E
Additional Comments:
*Addition of intraoperative (cardiac)
**Color Doppler includes Color Amplitude Doppler
Oolor Doppior instados Solor Include: B+PWD; B+Color; B+Amplitude; B+M;
Note 2: Combined modes include: B+M+Color
Note 2: Combined modes include: B+Color+PWD; B+Amplitude+PWD;
Note 3: Combined modes include: B+Color+PWD; B+Amplit
Note of Combined modes include: B+CWD; B+Color+CWD; B+Amplitude+CWD
Note 5: SonoCT
Note 6: Imaging for guidance of biopsy
Note 7: Infertility monitoring of follicle development
Note 7. Internity monitoring of follore development
Note 8: Extended Field of View (EFOV), AKA Panoramic Imaging includes SonoCT imaging
Note 9: EFOV including Amplitude Doppler
Note 10: Harmonic Imaging
Note 11: Contrast Imaging
Note 12: 3D Imaging
Note 13: XRES
Prescription Use (Per 21 CRF 801.109)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel A. Lyons
(Division Sign-Off) Division of Reproductive, Abdomi and Radiological Devic 510(k) Number _
{5}------------------------------------------------
# DIAGNOSTIC ULTRASOUND INDICATIONS FOR USE STATEMENT
510(k) Number: System: Transducer: Intended Use:
#### iU22 Ultrasound System
X3-1 XS-1
Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
| Clinical Application | | Mode of Operation (*includes simultaneous B-mode) | | | | | | |
|---------------------------|------------------------------|---------------------------------------------------|---|-----|-----|-------------------|----------------------|------------------------------|
| General
(Track I only) | Specific
(Tracks I & III) | B | M | PWD | CWD | Color
Doppler* | Combined*
(Spec.) | Other
(Spec.) |
| Ophthalmic | Ophthalmic | | | | | | | |
| | Fetal | P | P | P | | P | Notes 1, 3 | Notes 5, 6, 8, 10,
12, 13 |
| | Abdominal | P | P | P | | P | Notes 1,3 | Notes 5, 6, 8, 10,
12, 13 |
| | Intra-operative (cardiac) | N | N | N | | N | Notes 1,2,3 | Notes 10, 11, 12, 13 |
| | Intra-operative (Neuro.) | | | | | | | |
| Fetal Imaging | Laparoscopic | | | | | | | |
| & Other | Pediatric | | | | | | | |
| | Small Organ | | | | | | | |
| | Neonatal Cephalic | | | | | | | |
| | Adult Cephalic | | | | | | | |
| | Trans-rectal | | | | | | | |
| | Trans-vaginal | | | | | | | |
| | Trans-urethral | | | | | | | |
| | Trans-esoph. (non-Cardiac) | | | | | | | |
| | Musculo-skel. (Conventional) | | | | | | | |
| | Musculo-skel. (Superficial) | | | | | | | |
| | Intra-luminal | | | | | | | |
| | Other (Specify) | | | | | | | |
| | Cardiac Adult | N | N | N | N | N | Note 1 | Notes 10, 11, 12, 13 |
| Cardiac | Cardiac Pediatric | N | N | N | N | N | Notes 1, 2, 3 | Notes 10, 11, 12, 13 |
| | Trans-esophageal (Cardiac) | | | | | P | | |
| | Fetal Echo | P | P | P | | P | Notes 1, 2, 3 | Notes 5, 10, 12,13 |
| Peripheral | Peripheral vessel | | | | | | | |
| Vessel | Cerebral Vascular | | | | | | | |
N= new indication; P= previously cleared; E= added under Appendix E
Additional Comments:
*Color Doppler includes Color Amplitude Doppler
Oolor Doppior Inoladoo Ocieclude: B+PWD; B+Color; B+Amplitude; B+M;
Note 2: Combined modes include: B+M+Color
Note 2: Combined modes include: B+Color+PWD; B+Amplitude+PWD
Note 4: Combined modes include: B+CWD; B+Color+CWD; B+Amplitude+CWD
Note 5: SonoCT
Note 6: Imaging for guidance of biopsy
Note 7: Infertility monitoring of follicle development
Note 7. Internity monitoring of follors and of others.
Note 8: Extended Field of View (EFOV), AKA Panoramic Imaging includes SonoCT imaging
Note 9: EFOV including Amplitude Doppler
Note 10: Harmonic Imaging
Note 11: Contrast Imaging
Note 12: 3D Imaging
Note 12: YPES
Note 13: XRES
Prescription Use (Per 21 CRF 801.109) Concurrence of CDRH, Office of Device Evaluation (ODE)
Daniel A. Syson
(Division Sign-Off) Division of Reproductive, Abdominal, and Radiological Devices 510(k) Number _
{6}------------------------------------------------
#### Section 4.3
# DIAGNOSTIC ULTRASOUND INDICATIONS FOR USE STATEMENT
| 510(k) Number: |
|----------------|
| System: |
| Transducer: |
| Intended Use: |
iU22 Ultrasound System
\$5-1 53-1
Diagnostic ultrasound imaging or fluid flow analysis of the human body as follows:
| Clinical Application | | Mode of Operation (*includes simultaneous B-mode) | | | | | | |
|---------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------|---|-----|-----|-------------------|----------------------|------------------|
| General
(Track I only) | Specific
(Tracks I & III) | B | M | PWD | CWD | Color
Doppler* | Combined*
(Spec.) | Other
(Spec.) |
| Ophthalmic | Ophthalmic | | | | | | | |
| Fetal Imaging
& Other | Fetal
Abdominal
Intra-operative (cardiac)
Intra-operative (Neuro.)
Laparoscopic
Pediatric
Small Organ
Neonatal Cephalic
Adult Cephalic
Trans-rectal
Trans-vaginal
Trans-urethral
Trans-esoph. (non-Cardiac)
Musculo-skel. (Conventional)
Musculo-skel. (Superficial)
Intra-luminal | | | | | | | |
| | Other (Specify)
Cardiac Adult | E | E | E | E | E | Notes 1, 2 3,
4 | Notes 10, 11, 13 |
| Cardiac | Cardiac Pediatric | E | E | E | E | E | Notes 1, 2 3,
4 | Notes 10, 11, 13 |
| | Trans-esophageal (Cardiac)
Fetal Echo | | | | | | | |
| Peripheral
Vessel | Peripheral vessel
Cerebral Vascular | | | | | | | |
N= new indication; P= previously cleared; E= added under Appendix E
Additional Comments:
*Color Doppler includes Color Amplitude Doppler
Solor Dopping modes include: B+PWD; B+Color; B+Amplitude; B+M;
Note 2: Combined modes include: B+M+Color
Note 2: Combined modes include: B+Color+PWD; B+Amplitude+PWD
Note e: Combined modes include: B+CWD; B+Color+CWD; B+Amplitude+CWD
Note 5: SonoCT
Note 6: Imaging for guidance of biopsy
Note 7: Infertility monitoring of follicle development
Note 7. Infentify monitoring of follors devolusions
Note 8: Extended Field of View (EFOV), AKA Panoramic Imaging includes SonoCT imaging
Note 9: EFOV including Amplitude Doppler
Note 10: Harmonic Imaging
Note 11: Contrast Imaging
Note 12: 3D Imaging
Note 12, OD Rings
Note 13, YDES
Note 13: XRES
Prescription Use (Per 21 CRF 801.109) Concurrence of CDRH, Office of Device Evaluation (ODE)
David A. Lyman
(Division Sign-Off) Division of Reproductive, Abdominal, and Radining cal Devices 51(%) Number
---
**Source:** [https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/IYO/K042540](https://fda.innolitics.com/submissions/RA/subpart-b%E2%80%94diagnostic-devices/IYO/K042540)
**Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact).
**Cite:** Innolitics at https://innolitics.com